Wall Street's main indices experienced gains, led by healthcare stocks hitting record highs and easing oil prices. The Dow Jones rose by 0.97%, while the S&P 500 and Nasdaq also saw increases. Investors are closely monitoring corporate earnings amidst concerns about artificial i…
NVIDIA and Eli Lilly have both reported impressive quarterly earnings, showcasing their respective growth potential. NVIDIA's revenue surged by over 105% year-over-year, driven by…
As markets prepare for a potential Federal Reserve rate hike, analysts are making significant adjustments to their stock recommendations. Key names such as Eli Lilly, Etsy, and No…
Eli Lilly is targeting a revenue milestone of $100 billion by fiscal 2026, supported by strong growth in its incretin franchise and a bullish price target of $1,480. The company's…
The Defiance Large Cap ex-Mag 7 ETF (XMAG) has significantly outperformed the Roundhill Magnificent Seven ETF (MAGS) and the S&P 500 in 2026. XMAG has returned 16% year-to-date, w…
Apnimed is preparing for a $160 million initial public offering on the Nasdaq to support the development of its lead therapy for obstructive sleep apnoea (OSA). The Massachusetts-…
Scribe Therapeutics experienced a significant surge in its stock price, climbing approximately 67% on its first day of trading on the Nasdaq after raising $128.7 million in its in…
In a bold new initiative, the administration seeks to reassure investors that while psychedelic research faces hurdles, their bank accounts will float high above any mental health…
Eli Lilly's experimental obesity treatment, combining eloralintide and Mounjaro, has demonstrated an average weight loss of 23% in individuals with diabetes, highlighting its pote…
Novo Nordisk's stock fell by 7% after the company revealed its long-term growth strategy at a capital markets day, raising investor concerns about its ability to maintain its posi…